| Project/Area Number |
17K10687
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小田 竜也 筑波大学, 医学医療系, 教授 (20282353)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | レクチン / 糖鎖 / 膵癌 / 胃癌 / 大腸癌 / 悪性腫瘍 / ドラッグデリバリー / 分子標的治療 / 分子標的 / 新規がん治療 |
|---|
| Outline of Final Research Achievements |
The outermost coatings of cancer cells are composed of cell-specific glycan layers (glycocalyx).Lectins, proteins with glycan-binding potential, were evaluated for possible use as drug carriers in treatment of gastrointestinal malignancy. We constructed a tissue array using surgical specimens of gastrointestinal malignant tumor, labeled multiple endogenous lectins, and studied expression pattern of malignant tumors by organ by comprehensive lectin staining.
By the analysis of lectin staining using the tissue array of multiple carcinomas created in this study, we were able to identify lectins A and B that react specifically with tumor cells of gastric cancer and colon cancer.We are further analyzing these and are currently adjusting the drug fusion drug (Lectin-Drug conjugate), and would show the concept of utilizing lectins as drug carriers to target glycans on the cancer cell surface, highlighting new insights into cancer treatments.
|
| Academic Significance and Societal Importance of the Research Achievements |
様々な分子標的治療薬が開発されているが特異度の面で十分とはいえず、未だ手術を凌駕する薬剤は開発されていない。本研究はヒト由来の内因性レクチンの中から消化器悪性腫瘍表面糖鎖を特異的に認識する内在性レクチンを選定した。一方で正常組織の反応性も高く、内因性レクチンを改変せずに薬剤の担体としても用いることは困難であることも示唆した。
今後、レクチンの薬剤送達キャリアとしての高い能力による新たなDrug Delivery法によるがん治療戦略の基盤を形成する研究である。
|
